MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7850
-0.0311
-3.81%
After Hours: 0.8100 +0.025 +3.18% 18:02 10/19 EDT
OPEN
0.8055
PREV CLOSE
0.8161
HIGH
0.8281
LOW
0.7750
VOLUME
517.98K
TURNOVER
--
52 WEEK HIGH
1.486
52 WEEK LOW
0.2943
MARKET CAP
61.23M
P/E (TTM)
-1.8606
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vistagen Therapeutics receives listing extension from NASDAQ
Vistagen Therapeutics ([[VTGN]] +4.5%) received a notification letter from Nasdaq granting 180-day extension to regain compliance with Nasdaq's minimum bid price requirement.The Company now time until April 12, 2021 to meet the requirement."We believe we
Seekingalpha · 5d ago
Vistagen Therapeutics +4.5% on listing extension from NASDAQ
Vistagen Therapeutics ([[VTGN]] +4.5%) received a notification letter from Nasdaq granting 180-day extension to regain compliance with Nasdaq's minimum bid price requirement.The Company now time until April 12, 2021 to meet the requirement."We believe we
Seekingalpha · 5d ago
Nasdaq Grants VistaGen 180-Day Extension To Meet Minimum Bid Price Requirement
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ:VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other
Benzinga · 5d ago
VistaGen Reports New Data From Second Preclinical Study Of AV-101 In Combination With Probenecid
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 /PRNewswire/ --VistaGen Therapeutics(NASDAQ:VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression, and other central nervous
Benzinga · 09/03 12:36
VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression, and other central nervous system (CNS) disorders, today announced positive new data from the Company's second preclinical study of its oral investigational drug, AV-101,
PR Newswire · 09/03 12:30
(LD Micro) 360 Companies Set to Present - this Week
ACCESSWIRE · 08/31 22:00
VistaGen Therapeutics to Present at the LD Micro 500 Virtual Conference
PR Newswire · 08/27 12:30
VistaGen Therapeutics reports FQ1 results
VistaGen Therapeutics (VTGN): FQ1 GAAP EPS of -$0.07.Cash and cash equivalents of $1.5M.Shares +5.5%.Press Release
Seekingalpha · 08/13 20:43
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTGN. Analyze the recent business situations of VistaGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTGN stock price target is 4.500 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 3.78M
% Owned: 4.85%
Shares Outstanding: 78.00M
TypeInstitutionsShares
Increased
3
102.89K
New
8
130.57K
Decreased
3
43.29K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.67%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
President/Chief Scientific Officer/Director
H. Snodgrass
Chairman/Independent Director
Jon Saxe
President/Founder/Chief Scientific Officer/Director
H. Ralph Snodgrass
Chief Executive Officer/Director
Shawn Singh
Chief Financial Officer/Vice President/Secretary
Jerrold Dotson
Vice President
Mark McPartland
Other
Mark Smith
Independent Director
Ann Cunningham
Independent Director
Jerry Gin
Independent Director
Brian Underdown
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.